Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors—a PET study in schizophrenia

No abstract is available for this paper.

• Publication year

  2006

• Venue

  NeuroImage

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/J.NEUROIMAGE.2006.04.161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Spurious autobiographical memories of psychosis: a dopamine-gated neuroplasticity account for relapse and treatment-resistant psychosis

  2025cites this paper
• D3 dopamine receptors implicate a subtype of medium spiny neuron in the aversive effects of antipsychotic medications

  2025cites this paper
• Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée

  2024cites this paper
• Pharmacological modulation of dopamine receptors reveals distinct brain-wide networks associated with learning and motivation in non-human primates

  2023cites this paper
• Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders

  2023cites this paper
• Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice

  2023cites this paper
• Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders

  2022cites this paper
• Association between depression in chronic phase and future clinical outcome of patients with schizophrenia

  2022cites this paper
• Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy

  2022cites this paper
• Low-Dose Olanzapine in the Treatment of Adolescents with Anorexia Nervosa: An Observational Naturalistic Case–Control Study

  2022cites this paper
• Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

  2022cites this paper
• Dopamine partial agonists: a discrete class of antipsychotics

  2022cites this paper
• Une approche de la psychopharmacologie des premiers épisodes psychotiques axée sur le rétablissement

  2021cites this paper
• Prevalence, Influencing Factors, and Cognitive Characteristics of Depressive Symptoms in Elderly Patients with Schizophrenia

  2021cites this paper
• Brain microstructural properties related to subjective well-being: diffusion tensor imaging analysis

  2021cites this paper
• To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial

  2020cites this paper
• Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia

  2020cites this paper
• The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia

  2019cites this paper
• Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.

  2019cites this paper
• Subjective response to antipsychotics in bipolar disorders: A review of a neglected area

  2019cites this paper
• Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.

  2019cites this paper
• Acute anti-psychotic modulation of the structure and function of the brain

  2018cites this paper
• Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride

  2018cites this paper
• An experience sampling study on the ecological validity of the SWN-20: Indication that subjective well-being is associated with momentary affective states above and beyond psychosis susceptibility.

  2017cites this paper
• Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

  2017cites this paper
• Treating depressive episodes or symptoms in patients with schizophrenia

  2017cites this paper
• 2 Methodological Considerations 2 . 1 Search Strategy and Selection Criteria

  2017cites this paper
• Pharmacological interventions in clozapine-refractory schizophrenia

  2017cites this paper
• Motivational Deficits in Schizophrenia

  2016cites this paper
• Altered emotional experiences attributed to antipsychotic medications - A potential link with estimated dopamine D2 receptor occupancy.

  2016influential citation
• Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study

  2015cites this paper
• Antipsychotics and Amotivation

  2015cites this paper
• Boredom, dopamine, and the thrill of psychosis: psychiatry in a new key.

  2015cites this paper
• Striatal D2/3 Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome

  2015cites this paper
• Common polymorphisms in dopamine-related genes combine to produce a ‘schizophrenia-like' prefrontal hypoactivity

  2014cites this paper
• Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

  2014cites this paper
• Why are the outcomes in patients with schizophrenia so poor?

  2014cites this paper
• Impaired subjective well-being in schizophrenia is associated with reduced anterior cingulate activity during reward processing

  2014cites this paper
• Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis

  2013cites this paper
• Allostatic Load as a Tool for Monitoring Physiological Dysregulations and Comorbidities in Patients with Severe Mental Illnesses

  2013cites this paper
• Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).

  2013cites this paper
• Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double‐blind, crossover, placebo‐controlled trial

  2013influential citation
• Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

  2013cites this paper
• Discriminant analysis of functional optical topography for schizophrenia diagnosis

  2013cites this paper
• DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience.

  2013cites this paper
• Assessing Psychiatric Adverse Effects during Clinical Drug Development

  2012cites this paper
• Connecting the dots : new perspectives on stress and psychosis

  2012cites this paper
• POPPIES AND PTSD: OPIOID INFLUENCE ON A PRECLINCAL MODEL OFPOSTTRAUMATIC STRESS DISORDER.

  2012cites this paper
• No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial

  2012cites this paper
• Different safety profiles of risperidone and paliperidone extended‐release: a double‐blind, placebo‐controlled trial with healthy volunteers

  2012cites this paper
• The Dopamine Augmenter L-DOPA Does Not Affect Positive Mood in Healthy Human Volunteers

  2012cites this paper
• Enhanced Persistency of Resting and Active Periods of Locomotor Activity in Schizophrenia

  2012cites this paper
• Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.

  2012influential citation
• Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine

  2012cites this paper
• The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia

  2011cites this paper
• Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms

  2011cites this paper
• Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine

  2011cites this paper
• Dysphoria Associated with Neuroleptic Withdrawal in an Adolescent with Tourette's Disorder

  2011cites this paper
• Reconceptualizing Medication Adherence: Six Phases of Dynamic Adherence

  2011cites this paper
• Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine

  2011cites this paper
• Antipsychotic-Associated Mental Side Effects and Their Relationship to Dopamine D2 Receptor Occupancy in Striatal Subdivisions: A High-Resolution PET Study With [11C]Raclopride

  2011cites this paper
• All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

  2011cites this paper
• Relationship between improvements of subjective well‐being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics

  2011cites this paper
• Subjective Well-Being in Schizophrenia as Measured with the Subjective Well-Being Under Neuroleptic Treatment Scale: A Review

  2011influential citation
• Course and determinants of self‐esteem in people diagnosed with schizophrenia during psychiatric treatment

  2010cites this paper
• Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.

  2010cites this paper
• Model-based parametric study of frontostriatal abnormalities in schizophrenia patients

  2010cites this paper
• Analysis of antipsychotic dose reduction.

  2010cites this paper
• Disruption of conditioned reward association by typical and atypical antipsychotics.

  2010cites this paper
• Neurochemical imaging in schizophrenia.

  2010influential citation
• Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis.

  2009cites this paper
• Association of Adverse Drug Effects With Subjective Well-Being in Patients With Schizophrenia Receiving Stable Doses of Risperidone

  2009cites this paper
• Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

  2009cites this paper
• Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

  2009cites this paper
• The Hippocampus and Nucleus Accumbens as Potential Therapeutic Targets for Neurosurgical Intervention in Schizophrenia

  2009cites this paper
• The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.

  2009influential citation
• Cure or Curse? Ambivalent Attitudes Towards Neuroleptic Medication in Schizophrenia and Non-Schizophrenia Patients

  2009cites this paper
• Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

  2009cites this paper
• The subjective experience of taking antipsychotic medication: a content analysis of Internet data

  2009cites this paper
• Clinical Pharmacology in the Molecular Era

  2008cites this paper
• CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best?

  2008cites this paper
• A Comparative Pilot Study of Second-Generation Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders

  2008cites this paper
• Well-being and co-morbidity in recent onset schizophrenia

  2008cites this paper
• Subjective effects of antipsychotic drugs and their relevance for compliance and remission

  2008cites this paper
• The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

  2008cites this paper
• Current awareness in human psychopharmacology

  2008cites this paper
• Well-being and co-morbidity in recent onset schizophrenia

  2008cites this paper
• Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457

  2008cites this paper
• The role of dopamine for the pathophysiology of schizophrenia

  2007cites this paper
• Effects of dopaminergic modulation on electrophysiological brain response to affective stimuli

  2007cites this paper
• Anxiolytic-Like Effects of κ-Opioid Receptor Antagonists in Models of Unlearned and Learned Fear in Rats

  2007cites this paper
• Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers

  2007cites this paper
• Stress  induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis

  year unknowncites this paper